BCL2 and acute lymphoblastic leukemia: Venetoclax (ABT-199) that targets higher BCL-2 expression is in phase-I clinical trials as monotherapy for R/R malignancies including T-ALL (NCT03236857) and in combination with Low-Intensity Chemotherapy and Venetoclax in phase I/II for R/R B or T-ALL (NCT03808610).